The latest price target for Outlook Therapeutics (NASDAQ:OTLK) was reported by Guggenheim on January 17, 2025. The analyst firm set a price target for $12.00 expecting OTLK to rise to within 12 months (a possible 476.65% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Outlook Therapeutics (NASDAQ:OTLK) was provided by Guggenheim, and Outlook Therapeutics reiterated their buy rating.

The last upgrade for Outlook Therapeutics Inc happened on March 27, 2024 when BTIG raised their price target to $50. BTIG previously had a neutral for Outlook Therapeutics Inc.

The last downgrade for Outlook Therapeutics Inc happened on December 2, 2024 when Chardan Capital changed their price target from N/A to N/A for Outlook Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Outlook Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Outlook Therapeutics was filed on January 17, 2025 so you should expect the next rating to be made available sometime around January 17, 2026.

While ratings are subjective and will change, the latest Outlook Therapeutics (OTLK) rating was a reiterated with a price target of $12.00 to $12.00. The current price Outlook Therapeutics (OTLK) is trading at is $2.08, which is out of the analyst’s predicted range.